Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Short term Debt: 2011-2023

Historic Short term Debt for Ligand Pharmaceuticals (LGND) over the last 5 years, with Mar 2023 value amounting to $76.8 million.

  • Ligand Pharmaceuticals' Short term Debt was N/A to $76.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $76.8 million, marking a year-over-year change of. This contributed to the annual value of $76.7 million for FY2022, which is N/A change from last year.
  • Ligand Pharmaceuticals' Short term Debt amounted to $76.8 million in Q1 2023, which was up 0.12% from $76.7 million recorded in Q4 2022.
  • Ligand Pharmaceuticals' 5-year Short term Debt high stood at $115.0 million for Q2 2022, and its period low was $26.8 million during Q1 2019.
  • For the 2-year period, Ligand Pharmaceuticals' Short term Debt averaged around $86.3 million, with its median value being $76.7 million (2022).
  • Data for Ligand Pharmaceuticals' Short term Debt shows a maximum YoY tumbled of 93.25% (in 2019) over the last 5 years.
  • Over the past 3 years, Ligand Pharmaceuticals' Short term Debt (Quarterly) stood at $27.1 million in 2019, then followed by $76.7 million in 2022, then followed by $76.8 million in 2023.
  • Its last three reported values are $76.8 million in Q1 2023, $76.7 million for Q4 2022, and $76.6 million during Q3 2022.